Business context and reporting period
The supplied filing is Midatech Pharma plc’s Form 20-F annual report for the fiscal year ended December 31, 2017, filed April 23, 2018. It is not a quarterly report. The filing identifies the registrant as Midatech Pharma plc, not Biodexa Pharmaceuticals plc; investors should confirm that this is the intended company and filing.
Midatech develops drug-delivery platforms focused on oncology and immunotherapy and sells licensed oncology and supportive-care products in the United States. Its research and development pipeline uses gold nanoparticles, sustained-release microspheres and nano-inclusion technology. Financial statements are prepared under IFRS in pounds sterling.
Financial and operating highlights
| Metric | 2017 | 2016 |
|---|---|---|
| Product revenue | £6.758 million | £6.376 million |
| Grant revenue | £0.840 million | £0.547 million |
| Total revenue | £7.598 million | £6.923 million |
| Gross profit | £6.672 million | £6.256 million |
| Operating loss | £17.578 million | £30.586 million |
| Loss for the year | £16.064 million | £20.162 million |
| Operating cash flow | £12.953 million used | £13.086 million used |
| Cash and cash equivalents at year-end | £13.204 million | £17.608 million |
| Total borrowings at year-end | £6.546 million | £2.158 million |
| Total assets / total liabilities | £49.224 million / £14.548 million | £56.689 million / £10.965 million |
Product revenue was predominantly U.S.-based: £6.609 million in 2017, versus £5.850 million in 2016. Cost of sales was £0.926 million. Research and development spending rose 31% to £10.185 million; distribution, sales and marketing costs fell 25% to £9.417 million, partly because product-right amortization declined; administrative costs fell 38% to £3.148 million.
Financing activities generated £10.277 million in cash, including £5.728 million net proceeds from share issuance and approximately £5.237 million from the initial MidCap loan tranche. Investing activities used £1.470 million. The filing reports no dividends declared.
Material changes versus the prior year
- Total revenue grew about 10%; U.S. product sales increased, while European revenue fell to £0.149 million from £0.526 million.
- Net loss narrowed by about £4.1 million and operating loss by about £13.0 million. The comparison benefited substantially from the prior-year £11.413 million Oravig impairment; 2017 included a £1.500 million impairment for the suspended Opsisporin program.
- Cash declined £4.404 million during 2017, despite the share placing and new debt. Borrowings increased following the MidCap financing.
- The 2017 loss-per-share figure improved to 31 pence from 56 pence, while weighted-average ordinary shares increased to approximately 51.3 million from 36.1 million.
Outlook, risks and unusual items
- Going concern and financing: The auditor included a going-concern uncertainty emphasis paragraph, citing recurring losses and substantial doubt. Management said additional financing was likely to be needed within 12 months. The company had £13.2 million cash at year-end and stated existing funds were insufficient for its expected needs; the board was exploring non-dilutive options and could defer development spending if financing were unavailable. The financial statements were prepared on a going-concern basis.
- Debt: The December 2017 MidCap facility provides up to $15 million in three tranches, maturing December 29, 2021. Midatech drew $7 million initially; further $3 million and $5 million tranches depend on development/regulatory milestones and warrant arrangements. Interest is LIBOR, subject to a 1.25% floor, plus 7.50%. The facility is secured against borrower assets and includes restrictive covenants.
- Pipeline expectations: Management expected Q-Octreotide first-in-human work in 2018, with Phase I results anticipated in the second half of 2018 and a subsequent study targeted for results in the first half of 2019. MTX110 had FDA IND clearance for a planned Phase I/II DIPG study, subject to institutional review approvals. MTD119 remained preclinical, with an IND submission targeted for the first half of 2019 if studies were favorable. These are forward-looking plans, not assured outcomes.
- Commercial and portfolio risks: Oravig had underperformed in a genericized market and was impaired in 2016. Opsisporin development was suspended and impaired in 2017. The company cited competition, clinical and regulatory uncertainty, reimbursement and pricing pressure, third-party supply and collaboration dependence, and foreign-exchange exposure.
- Other events and controls: CEO James Phillips was scheduled to depart at the end of May 2018, with Craig Cook appointed as successor effective June 1. Management reported that a 2016 material weakness involving classification of sales credits was remediated in 2017; management concluded year-end 2017 internal control over financial reporting was effective. The independent auditor did not provide an internal-control attestation.
Important facts for investors to verify
- Confirm the issuer identity: the filing is for Midatech Pharma plc, whereas the request metadata names Biodexa Pharmaceuticals plc.
- Review the going-concern disclosure, cash runway assumptions and the status, timing and terms of any financing after year-end.
- Check MidCap covenant compliance, security over assets, interest costs and the conditions for accessing the undrawn tranches.
- Track actual U.S. product sales, including product-level performance, and compare them with the assumptions supporting intangible-asset valuations.
- Verify clinical trial starts, approvals, results and funding for Q-Octreotide, MTX110 and MTD119 against the stated targets.
- Assess the effect of share issuance, warrants and potential further financing on dilution, and monitor any further impairment or internal-control disclosures.